369 related articles for article (PubMed ID: 24292068)
21. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
Adams OJ; Stanczak MA; von Gunten S; Läubli H
Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
[TBL] [Abstract][Full Text] [Related]
22. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.
Beatson R; Tajadura-Ortega V; Achkova D; Picco G; Tsourouktsoglou TD; Klausing S; Hillier M; Maher J; Noll T; Crocker PR; Taylor-Papadimitriou J; Burchell JM
Nat Immunol; 2016 Nov; 17(11):1273-1281. PubMed ID: 27595232
[TBL] [Abstract][Full Text] [Related]
23. Glycocalyx Engineering with a Recycling Glycopolymer that Increases Cell Survival In Vivo.
Woods EC; Yee NA; Shen J; Bertozzi CR
Angew Chem Int Ed Engl; 2015 Dec; 54(52):15782-8. PubMed ID: 26647316
[TBL] [Abstract][Full Text] [Related]
24. Siglec-7 Defines a Highly Functional Natural Killer Cell Subset and Inhibits Cell-Mediated Activities.
Shao JY; Yin WW; Zhang QF; Liu Q; Peng ML; Hu HD; Hu P; Ren H; Zhang DZ
Scand J Immunol; 2016 Sep; 84(3):182-90. PubMed ID: 27312286
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.
Angata T; Nycholat CM; Macauley MS
Trends Pharmacol Sci; 2015 Oct; 36(10):645-660. PubMed ID: 26435210
[TBL] [Abstract][Full Text] [Related]
26. Live-Cell Labeling of Specific Protein Glycoforms by Proximity-Enhanced Bioorthogonal Ligation.
Robinson PV; de Almeida-Escobedo G; de Groot AE; McKechnie JL; Bertozzi CR
J Am Chem Soc; 2015 Aug; 137(33):10452-5. PubMed ID: 26280358
[TBL] [Abstract][Full Text] [Related]
27. Siglecs: A journey through the evolution of sialic acid-binding immunoglobulin-type lectins.
Bornhöfft KF; Goldammer T; Rebl A; Galuska SP
Dev Comp Immunol; 2018 Sep; 86():219-231. PubMed ID: 29751010
[TBL] [Abstract][Full Text] [Related]
28. Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities.
Rodrigues E; Macauley MS
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29912148
[TBL] [Abstract][Full Text] [Related]
29. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.
Stanczak MA; Siddiqui SS; Trefny MP; Thommen DS; Boligan KF; von Gunten S; Tzankov A; Tietze L; Lardinois D; Heinzelmann-Schwarz V; von Bergwelt-Baildon M; Zhang W; Lenz HJ; Han Y; Amos CI; Syedbasha M; Egli A; Stenner F; Speiser DE; Varki A; Zippelius A; Läubli H
J Clin Invest; 2018 Nov; 128(11):4912-4923. PubMed ID: 30130255
[TBL] [Abstract][Full Text] [Related]
30. Sialic acids sweeten a tumor's life.
Büll C; Stoel MA; den Brok MH; Adema GJ
Cancer Res; 2014 Jun; 74(12):3199-204. PubMed ID: 24830719
[TBL] [Abstract][Full Text] [Related]
31. A bulky glycocalyx fosters metastasis formation by promoting G1 cell cycle progression.
Woods EC; Kai F; Barnes JM; Pedram K; Pickup MW; Hollander MJ; Weaver VM; Bertozzi CR
Elife; 2017 Dec; 6():. PubMed ID: 29266001
[TBL] [Abstract][Full Text] [Related]
32. Sialic acids in cancer biology and immunity.
Pearce OM; Läubli H
Glycobiology; 2016 Feb; 26(2):111-28. PubMed ID: 26518624
[TBL] [Abstract][Full Text] [Related]
33. Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells.
Perdicchio M; Ilarregui JM; Verstege MI; Cornelissen LA; Schetters ST; Engels S; Ambrosini M; Kalay H; Veninga H; den Haan JM; van Berkel LA; Samsom JN; Crocker PR; Sparwasser T; Berod L; Garcia-Vallejo JJ; van Kooyk Y; Unger WW
Proc Natl Acad Sci U S A; 2016 Mar; 113(12):3329-34. PubMed ID: 26941238
[TBL] [Abstract][Full Text] [Related]
34. Influencing Early Stages of Neuromuscular Junction Formation through Glycocalyx Engineering.
Huang ML; Tota EM; Lucas TM; Godula K
ACS Chem Neurosci; 2018 Dec; 9(12):3086-3093. PubMed ID: 30095249
[TBL] [Abstract][Full Text] [Related]
35. Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation.
Spence S; Greene MK; Fay F; Hams E; Saunders SP; Hamid U; Fitzgerald M; Beck J; Bains BK; Smyth P; Themistou E; Small DM; Schmid D; O'Kane CM; Fitzgerald DC; Abdelghany SM; Johnston JA; Fallon PG; Burrows JF; McAuley DF; Kissenpfennig A; Scott CJ
Sci Transl Med; 2015 Sep; 7(303):303ra140. PubMed ID: 26333936
[TBL] [Abstract][Full Text] [Related]
36. Immature truncated O-glycophenotype of cancer directly induces oncogenic features.
Radhakrishnan P; Dabelsteen S; Madsen FB; Francavilla C; Kopp KL; Steentoft C; Vakhrushev SY; Olsen JV; Hansen L; Bennett EP; Woetmann A; Yin G; Chen L; Song H; Bak M; Hlady RA; Peters SL; Opavsky R; Thode C; Qvortrup K; Schjoldager KT; Clausen H; Hollingsworth MA; Wandall HH
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):E4066-75. PubMed ID: 25118277
[TBL] [Abstract][Full Text] [Related]
37. Sialic acids and autoimmune disease.
Mahajan VS; Pillai S
Immunol Rev; 2016 Jan; 269(1):145-61. PubMed ID: 26683151
[TBL] [Abstract][Full Text] [Related]
38. Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread.
Büll C; Boltje TJ; van Dinther EA; Peters T; de Graaf AM; Leusen JH; Kreutz M; Figdor CG; den Brok MH; Adema GJ
ACS Nano; 2015 Jan; 9(1):733-45. PubMed ID: 25575241
[TBL] [Abstract][Full Text] [Related]
39. Sweet escape: sialic acids in tumor immune evasion.
Büll C; den Brok MH; Adema GJ
Biochim Biophys Acta; 2014 Aug; 1846(1):238-46. PubMed ID: 25026312
[TBL] [Abstract][Full Text] [Related]
40. Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development.
Agarwal P; Bertozzi CR
Bioconjug Chem; 2015 Feb; 26(2):176-92. PubMed ID: 25494884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
